Oppenheimer Asset Management Inc. Makes New Investment in Becton, Dickinson and Company $BDX

Oppenheimer Asset Management Inc. bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 90,788 shares of the medical instruments supplier’s stock, valued at approximately $13,739,000.

A number of other hedge funds have also recently modified their holdings of BDX. Imprint Wealth LLC bought a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $25,000. SHP Wealth Management bought a new position in Becton, Dickinson and Company in the 4th quarter valued at $26,000. Prosperity Bancshares Inc purchased a new stake in Becton, Dickinson and Company in the fourth quarter worth $29,000. WPG Advisers LLC lifted its position in shares of Becton, Dickinson and Company by 64.2% during the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 61 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC bought a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth $32,000. Institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Wells Fargo & Company upped their price target on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Piper Sandler upped their target price on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Citigroup reaffirmed a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday. Finally, The Goldman Sachs Group decreased their price target on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday, May 27th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $185.67.

Insider Activity

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 11,779 shares of company stock worth $1,974,669. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.7%

NYSE:BDX opened at $183.16 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The company has a 50-day moving average of $157.84 and a 200 day moving average of $161.70. The firm has a market cap of $50.47 billion, a PE ratio of 55.17, a price-to-earnings-growth ratio of 12.82 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter last year, the firm posted $3.68 EPS. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.